CFDs are complex instruments and come with a high risk of losing money rapidly due to leverage. 87.41% of retail investor accounts lose money when trading CFDs with this provider. You should consider whether you understand how CFDs work and whether you can afford to take the high risk of losing your money.

Scan to Download iOS&Android APP

Trade 3SBio Inc. - 1530 CFD

8.05
1.26%
0.35
Low: 7.95
High: 8.1
Market Trading Hours* (UTC) Opens on Thursday at 01:30

Mon - Fri: 01:30 - 04:00 05:00 - 08:00

  • Summary
  • Historical Data
  • Events
  • Income Statement
  • Balance Sheet
  • Cash Flow
  • Ownership
Trading Conditions
Spread 0.35
Long position overnight fee

Long position overnight fee


Margin. Your investment $1,000.00
Overnight fee -0.0295 %
Charges from borrowed part ($-1.18)
Trade size with leverage ~ $5,000.00
Money from leverage ~ $4,000.00

Go to platform
-0.0295%
Short position overnight fee

Short position overnight fee


Margin. Your investment $1,000.00
Overnight fee -0.0295 %
Charges from borrowed part ($-1.18)
Trade size with leverage ~ $5,000.00
Money from leverage ~ $4,000.00

Go to platform
-0.0149%
Overnight fee time 22:00 (UTC)
Min traded quantity 1
Currency HKD
Margin 20%
Stock exchange Hong Kong
Commission on trade 0%

*Information provided by Capital.com

3SBio Inc ESG Risk Ratings

High Medium Low Negligible

‘B’ score indicates good relative ESG performance and above average degree of transparency in reporting material ESG data publicly.

More ESG coverage

Key Stats
Prev. Close* 7.95
Open* 7.95
1-Year Change* 22.31%
Day's Range* 7.95 - 7.95
52 wk Range 4.72-7.98
Average Volume (10 days) 23.9618
Average Volume (3 months) 394.411
Market Cap 19364.4
P/E Ratio 11.5487
Shares Outstanding 2438850000
Revenue 6971.22
EPS 0.68753
Dividend (Yield %) 2.51889
Beta 1.01142
Next Earnings Date Mar 28, 2023

All data is provided by Refinitiv, except for data marked with an asterisk, which is *data provided by Capital.com

  • Last Week
  • Last Month
  • Last Year
  • Last two Years
  • Max
  • Daily
  • Weekly
  • Monthly
Date Close Change Change (%) Open High Low
Nov 30, 2022 8.05 0.05 0.63% 8.00 8.10 7.95
Nov 29, 2022 7.95 0.10 1.27% 7.85 8.00 7.85
Nov 28, 2022 7.95 0.10 1.27% 7.85 8.00 7.50
Nov 25, 2022 7.90 0.10 1.28% 7.80 7.90 7.75
Nov 24, 2022 7.80 0.00 0.00% 7.80 7.85 7.65
Nov 23, 2022 7.80 0.20 2.63% 7.60 7.80 7.55
Nov 22, 2022 7.65 0.45 6.25% 7.20 7.70 7.15
Nov 21, 2022 7.25 0.50 7.41% 6.75 7.30 6.60
Nov 18, 2022 6.70 -0.20 -2.90% 6.90 6.95 6.70
Nov 17, 2022 6.85 -0.05 -0.72% 6.90 6.95 6.65
Nov 16, 2022 6.95 0.20 2.96% 6.75 7.05 6.75
Nov 15, 2022 6.85 -0.40 -5.52% 7.25 7.35 6.85
Nov 14, 2022 7.25 0.05 0.69% 7.20 7.30 7.05
Nov 11, 2022 7.10 0.25 3.65% 6.85 7.15 6.75
Nov 10, 2022 6.65 0.50 8.13% 6.15 6.65 6.05
Nov 9, 2022 6.20 0.15 2.48% 6.05 6.40 6.00
Nov 8, 2022 6.00 0.10 1.69% 5.90 6.15 5.85
Nov 7, 2022 5.80 0.05 0.87% 5.75 5.90 5.65
Nov 4, 2022 5.70 0.10 1.79% 5.60 5.85 5.60
Nov 3, 2022 5.60 -0.15 -2.61% 5.75 5.75 5.50

3SBio Inc. Events

Time (UTC) Country Event
No events scheduled
View all events
  • Annual
  • Quarterly
2016 2017 2018 2019 2020 2021
Total revenue 2797.29 3734.33 4583.87 5318.09 5587.64 6382.01
Revenue 2797.29 3734.33 4583.87 5318.09 5587.64 6382.01
Cost of Revenue, Total 402.268 676.235 877.255 925.347 1062.91 1106.29
Gross Profit 2395.02 3058.1 3706.61 4392.74 4524.73 5275.72
Total Operating Expense 1787.33 2476.52 2941.73 3974.57 4497.05 4409.62
Selling/General/Admin. Expenses, Total 1315.9 1662.71 2075.93 2668.55 2480 2803.02
Research & Development 243.006 257.31 362.706 526.565 590.343 753.872
Interest Expense (Income) - Net Operating -25.552 1.574 -348.558 -131.48 158.997 -237.673
Unusual Expense (Income) -65.598 -88.991 10.054 3.367 178.195 27.409
Other Operating Expenses, Total -82.691 -32.312 -35.66 -17.779 26.599 -43.3
Operating Income 1009.96 1257.81 1642.14 1343.52 1090.59 1972.39
Interest Income (Expense), Net Non-Operating -159.892 -155.792 -146.627 -120.507 -111.459 -103.626
Net Income Before Taxes 850.068 1102.02 1495.51 1223.01 979.129 1868.77
Net Income After Taxes 714.254 924.404 1277.25 980.228 771.106 1627.57
Minority Interest -1.69 10.985 -0.079 -6.511 64.685 23.674
Net Income Before Extra. Items 712.564 935.389 1277.17 973.717 835.791 1651.25
Net Income 712.564 935.389 1277.17 973.717 835.791 1651.25
Income Available to Common Excl. Extra. Items 712.564 935.389 1277.17 973.717 835.791 1651.25
Income Available to Common Incl. Extra. Items 712.564 935.389 1277.17 973.717 835.791 1651.25
Diluted Net Income 712.564 966.78 1349.94 973.717 835.791 1651.25
Diluted Weighted Average Shares 2563.49 2653.55 2754.04 2537.74 2750.82 2770.12
Diluted EPS Excluding Extraordinary Items 0.27797 0.36433 0.49017 0.38369 0.30383 0.59609
Dividends per Share - Common Stock Primary Issue 0 0.05705 0 0.16296
Diluted Normalized EPS 0.25647 0.3362 0.49329 0.38476 0.35485 0.60471
Dilution Adjustment 31.391 72.773
Q4 2019 Q2 2020 Q4 2020 Q2 2021 Q4 2021
Total revenue 2675.16 2695.18 2892.46 3107.14 3274.87
Revenue 2675.16 2695.18 2892.46 3107.14 3274.87
Cost of Revenue, Total 466.937 478.097 584.814 519.991 586.295
Gross Profit 2208.22 2217.08 2307.65 2587.14 2688.58
Total Operating Expense 1785.66 1815.02 2682.03 2032.6 2377.01
Selling/General/Admin. Expenses, Total 1153.04 1129.25 1350.75 1314.8 1488.22
Research & Development 262.674 254.348 335.995 344.851 409.021
Interest Expense (Income) - Net Operating -94.483 -44.052 203.049 -107.535 -130.138
Unusual Expense (Income) 2.674 1.827 176.368 -16.086 43.495
Other Operating Expenses, Total -5.184 -4.452 31.051 -23.42 -19.88
Operating Income 889.499 880.155 210.433 1074.53 897.86
Interest Income (Expense), Net Non-Operating -73.071 -61.579 -49.88 -48.679 -54.947
Net Income Before Taxes 816.428 818.576 160.553 1025.85 842.913
Net Income After Taxes 669.027 685.747 85.359 891.025 736.548
Minority Interest -16.604 16.735 47.95 7.883 15.791
Net Income Before Extra. Items 652.423 702.482 133.309 898.908 752.339
Net Income 652.423 702.482 133.309 898.908 752.339
Income Available to Common Excl. Extra. Items 652.423 702.482 133.309 898.908 752.339
Income Available to Common Incl. Extra. Items 652.423 702.482 133.309 898.908 752.339
Diluted Net Income 652.423 736.306 99.485 929.591 721.656
Diluted Weighted Average Shares 2539.26 2731.41 2770.23 2766.5 2773.74
Diluted EPS Excluding Extraordinary Items 0.25693 0.26957 0.03591 0.33602 0.26017
Diluted Normalized EPS 0.2578 0.27013 0.06976 0.33097 0.27388
Dilution Adjustment 33.824 -33.824 30.683 -30.683
Dividends per Share - Common Stock Primary Issue 0 0 0.16296
  • Annual
  • Quarterly
2016 2017 2018 2019 2020 2021
Total Current Assets 2240.73 5276.22 4437.53 4596.18 6679.91 7790.7
Cash and Short Term Investments 1039.77 3103.19 1860.74 2555.01 4363.7 4768.1
Cash & Equivalents 677.598 2398.62 1792.6 2082.85 3090.83 2868.08
Short Term Investments 362.172 704.564 68.132 472.163 1272.86 1900.02
Total Receivables, Net 904.221 1754.36 2141.37 1464.67 1534.66 1866.31
Accounts Receivable - Trade, Net 676.776 1185.78 1347.03 930.78 860.001 1288.83
Total Inventory 262.438 376.529 384.609 528.473 619.508 690.523
Prepaid Expenses 22.303 28.97 36.511 25.951 36.222 281.174
Other Current Assets, Total 11.999 13.167 14.305 22.073 125.823 184.592
Total Assets 11038.8 13753 13839.7 14809.3 17678.2 19212.6
Property/Plant/Equipment, Total - Net 1800.78 1759.67 1791.96 2324.73 2979.39 3828.25
Property/Plant/Equipment, Total - Gross 2389.87 2375.63 2532.97 3243.17 4075.5 5086.33
Accumulated Depreciation, Total -589.086 -615.962 -741.009 -918.436 -1096.11 -1258.08
Goodwill, Net 4126.18 3923.6 4089.06 4145.9 3918.92 3843.88
Intangibles, Net 2288.5 2253.52 2298.74 2165.14 1898.48 1849.16
Long Term Investments 135.709 81.843 701.596 1277.87 1654.38 1321.27
Note Receivable - Long Term 79.517 35.372 28.758 6.555 2.2 0
Other Long Term Assets, Total 367.381 422.757 492.008 292.933 544.91 579.31
Total Current Liabilities 1143.62 2195.81 1655.54 1611.73 1450.92 1419.99
Accounts Payable 58.792 274.568 112.915 149.763 203.286 230.407
Accrued Expenses 303.653 420.184 567.412 595.441 446.623 568.023
Notes Payable/Short Term Debt 0 0 0 0 0 0
Current Port. of LT Debt/Capital Leases 518.461 1087.47 570.328 489.424 367.158 160.753
Other Current Liabilities, Total 262.713 413.591 404.886 377.101 433.854 460.806
Total Liabilities 4516.3 6356.18 5225.22 5184.27 6988.88 6985.12
Total Long Term Debt 2540.68 3318.67 2724.34 2322 2546.96 2468.13
Long Term Debt 2540.68 3318.67 2724.34 2318.04 2514.74 2435.75
Deferred Income Tax 294.396 280.268 270.761 268.077 272.242 264.468
Minority Interest 243.843 232.858 292.937 734.278 2404.02 2430.35
Other Liabilities, Total 293.763 328.583 281.64 248.181 314.736 402.195
Total Equity 6522.5 7396.79 8614.43 9625.04 10689.3 12227.5
Common Stock 0.155 0.156 0.156 0.155 0.155 0.155
Additional Paid-In Capital 4547.14 4568.25 4585.73 4553.41 4645.02 4490.38
Retained Earnings (Accumulated Deficit) 1816.33 2751.72 3894.37 4868.09 5704.9 7534.44
Unrealized Gain (Loss) 0.057 -4.393 0.157 1.052 197.089 98.378
Other Equity, Total 158.821 81.058 174.597 202.329 142.15 104.103
Total Liabilities & Shareholders’ Equity 11038.8 13753 13839.7 14809.3 17678.2 19212.6
Total Common Shares Outstanding 2532.31 2538.8 2543.71 2535.05 2543.6 2522.36
Treasury Stock - Common -40.586 0
Capital Lease Obligations 3.964 32.219 32.38
Dec 2019 Jun 2020 Dec 2020 Jun 2021 Dec 2021
Total Current Assets 4596.18 6871.76 6679.91 7401.7 7790.7
Cash and Short Term Investments 2555.01 4592.43 4363.7 4801.58 4768.1
Cash & Equivalents 2082.85 3793.11 3090.83 2919.68 2868.08
Short Term Investments 472.163 799.321 1272.86 1881.9 1900.02
Total Receivables, Net 1018.27 1182.39 982.965 1224.1 1378.76
Accounts Receivable - Trade, Net 930.78 1143.89 860.001 1153.44 1288.83
Total Inventory 528.473 569.884 619.508 681.498 690.523
Prepaid Expenses 472.36 504.847 587.917 582.659 768.726
Other Current Assets, Total 22.073 22.204 125.823 111.864 184.592
Total Assets 14809.3 17603.4 17678.2 18541.2 19212.6
Property/Plant/Equipment, Total - Net 2324.73 2455.11 2979.39 3435.99 3828.25
Goodwill, Net 4145.9 4197.85 3918.92 3886.33 3843.88
Intangibles, Net 2165.14 2118.73 1898.48 1851.26 1849.16
Long Term Investments 1277.87 1517.32 1654.38 1428.62 1321.27
Note Receivable - Long Term 6.555 3.576 2.2 0 0
Other Long Term Assets, Total 292.933 439.094 544.91 537.349 579.31
Total Current Liabilities 1611.73 1651.35 1450.92 1334.97 1419.99
Accounts Payable 149.763 166.198 203.286 214.946 230.407
Accrued Expenses 595.441 648.871 446.623 526.411 568.023
Notes Payable/Short Term Debt 0 0 0 0 0
Current Port. of LT Debt/Capital Leases 489.424 467.458 367.158 159.426 160.753
Other Current Liabilities, Total 377.101 368.823 433.854 434.183 460.806
Total Liabilities 5184.27 6926.82 6988.88 6808.73 6985.12
Total Long Term Debt 2322 3947.49 2546.96 2485.98 2468.13
Long Term Debt 2318.04 3920.38 2514.74 2452.38 2435.75
Capital Lease Obligations 3.964 27.11 32.219 33.601 32.38
Deferred Income Tax 268.077 274.327 272.242 266.194 264.468
Minority Interest 734.278 817.543 2404.02 2396.14 2430.35
Other Liabilities, Total 248.181 236.104 314.736 325.455 402.195
Total Equity 9625.04 10676.6 10689.3 11732.5 12227.5
Common Stock 0.155 0.155 0.155 0.156 0.155
Additional Paid-In Capital 4553.41 4553.19 4645.02 4665.96 4490.38
Retained Earnings (Accumulated Deficit) 4868.09 5570.57 5704.9 6777.63 7534.44
Treasury Stock - Common 0
Unrealized Gain (Loss) 1.052 216.446 197.089 162.96 98.378
Other Equity, Total 202.329 336.252 142.15 125.803 104.103
Total Liabilities & Shareholders’ Equity 14809.3 17603.4 17678.2 18541.2 19212.6
Total Common Shares Outstanding 2535.05 2538.53 2543.6 2549.25 2522.36
  • Annual
  • Quarterly
2016 2017 2018 2019 2020 2021
Net income/Starting Line 850.068 1102.02 1495.51 1223.01 979.129 1868.77
Cash From Operating Activities 1004.32 1074.1 1150.25 1887.38 1344.56 1578.34
Cash From Operating Activities 102.338 128.453 165.248 198.9 204.383 205.65
Amortization 58.662 115.242 148.016 135.068 156.554 123.352
Non-Cash Items 111.989 104.647 -152.08 341.251 560.395 -0.169
Cash Taxes Paid 122.244 130.286 263.338 355.329 254.046 286.822
Cash Interest Paid 131.805 125.741 66.968 38.236 196.078 6.262
Changes in Working Capital -118.733 -376.261 -506.444 -10.848 -555.9 -619.254
Cash From Investing Activities -4381.01 -643.215 -405.912 -1133.72 -1869.48 -1286.52
Capital Expenditures -466.035 -259.237 -462.396 -486.253 -981.473 -1145.77
Other Investing Cash Flow Items, Total -3914.97 -383.978 56.484 -647.464 -888.008 -140.743
Cash From Financing Activities 2710.21 1317.73 -1389.68 -454.4 1550.69 -481.119
Financing Cash Flow Items 192.643 -169.26 -9.427 108.099 1533.48 36.413
Issuance (Retirement) of Stock, Net 0 -40.586 -31.046 -10.12 -408.764
Issuance (Retirement) of Debt, Net 2517.56 1486.99 -1188.85 -515.114 27.326 -108.768
Foreign Exchange Effects 44.678 -27.592 39.323 -9.025 -17.778 -33.468
Net Change in Cash -621.8 1721.02 -606.016 290.242 1007.99 -222.758
Total Cash Dividends Paid -150.813 -16.339 0
Dec 2019 Jun 2020 Dec 2020 Jun 2021 Dec 2021
Net income/Starting Line 1223.01 818.576 979.129 1025.85 1868.77
Cash From Operating Activities 1887.38 708.237 1344.56 811.497 1578.34
Cash From Operating Activities 198.9 100.22 204.383 99.91 205.65
Amortization 135.068 74.305 156.554 59.811 123.352
Non-Cash Items 341.251 19.787 560.395 -79.445 -0.169
Cash Taxes Paid 355.329 73.849 254.046 123.958 286.822
Cash Interest Paid 38.236 6.834 196.078 1.552 6.262
Changes in Working Capital -10.848 -304.651 -555.9 -294.632 -619.254
Cash From Investing Activities -1133.72 -657.479 -1869.48 -765.999 -1286.52
Capital Expenditures -486.253 -335.578 -981.473 -530.541 -1145.77
Other Investing Cash Flow Items, Total -647.464 -321.901 -888.008 -235.458 -140.743
Cash From Financing Activities -454.4 1640.68 1550.69 -202.947 -481.119
Financing Cash Flow Items 108.099 97.69 1533.48 -0.987 36.413
Total Cash Dividends Paid -16.339 0
Issuance (Retirement) of Stock, Net -31.046 -10.906 -10.12 4.133 -408.764
Issuance (Retirement) of Debt, Net -515.114 1553.89 27.326 -206.093 -108.768
Foreign Exchange Effects -9.025 18.824 -17.778 -13.703 -33.468
Net Change in Cash 290.242 1710.26 1007.99 -171.152 -222.758

Why choose Capital.com? Our numbers speak for themselves.

Capital.com Group
475000+

Traders

71000+

Active clients monthly

$51000000+

Monthly investing volume

$30000000+

Withdrawn each month

Trading calculator

Calculate your hypothetical P&L if you had opened a CFD trade on a certain date (select a date) and closed on a different date (select a date).

Trade commission
0
  • 1:1
  • 2:1
  • 5:1
  • 10:1
  • 20:1
Leverage
20:1
  • 20
  • 100
  • 500
  • 1000
  • 10000
Investment
Trade size (Leverage x Investement):
Open

Close

Short Long

3SBio Company profile

3SBio Inc. develops, manufactures, markets, and sells biopharmaceuticals. The company's primary products include TPIAO, a recombinant human thrombopoietin for thrombocytopenia; Yisaipu, a tumour necrosis factor for treating rheumatoid arthritis, ankylosing spondylitis, and psoriasis; and EPIAO, a recombinant human erythropoietin for the treatment of anemia associated with chronic kidney disease (CKD), chemotherapy-induced anemia, and reduction of allogeneic blood transfusion in surgery patients. Its primary products also comprise SEPO, a recombinant human erythropoietin for anemia associated with CKD and chemotherapy; Byetta/Bydureon, an exenatide injection to improve glycemic control in adults with type-2 diabetes mellitus; and Qiming Keli for retinopathy caused by type-2 diabetes. In addition, the company offers Ruisiyi to treat advanced breast cancer; Wanwei for treating vomiting caused by cytotoxic chemotherapy; and Intefen to treat lymphatic or hematopoietic malignancies and viral infections. Further, it provides Inleusin for renal cell carcinoma, melanoma, thoracic fluid build-up caused by cancer, and tuberculosis; Etanercept for moderate to severe rheumatoid arthritis and plaque psoriasis, and active ankylosing spondylitis; and Sparin for prophylaxis and vein thrombosis, and to prevent clotting during hemodialysis. Additionally, the company offers Mandi for male-pattern alopecia and alopecia areata; Aiyishu for iron-deficiency anemia; Disu to prevent and treat chronic bronchitis, colds, and asthma; Jiannipai to prevent acute rejection after renal transplantation; and Humulin for diabetes, as well as contract development and manufacturing, trading, project management and consultation, and technology services. The company markets its products through in-house sales and marketing team, as well as distributors and third-party promoters. 3SBio Inc. was incorporated in 2006 and is headquartered in Shenyang, the People's Republic of China.
Industry: Biopharmaceuticals

瀋陽經濟技術開發區十號路1甲3號
SHENYANG
LIAONING
CN

Income Statement

People also watch

BTC/USD

16,922.05 Price
+2.650% 1D Chg, %
Long position overnight fee -0.0500%
Short position overnight fee 0.0140%
Overnight fee time 22:00 (UTC)
Spread 66.00

Oil - Crude

78.84 Price
-0.280% 1D Chg, %
Long position overnight fee -0.0108%
Short position overnight fee -0.0029%
Overnight fee time 22:00 (UTC)
Spread 0.03

US100

11,547.60 Price
+0.320% 1D Chg, %
Long position overnight fee -0.0167%
Short position overnight fee 0.0059%
Overnight fee time 22:00 (UTC)
Spread 1.8

Natural Gas

7.19 Price
-1.340% 1D Chg, %
Long position overnight fee 0.0600%
Short position overnight fee -0.0890%
Overnight fee time 22:00 (UTC)
Spread 0.005

Still looking for a broker you can trust?

Join the 475.000+ traders worldwide that chose to trade with Capital.com

1. Create & verify your account 2. Make your first deposit 3. You’re all set. Start trading